Last reviewed · How we verify

NCT07435480

Irisin Hormone as a Novel Diagnostic Marker for Detection and Progression of Diabetic Nephrophathy Patients

Not yet recruiting Last updated 10 March 2026
What this trial tests

trial testing HBa1c in Diabetic Nephropathies in 200 participants. Not yet recruiting.

Timeline
1 April 2026
Primary endpoint
1 March 2027
1 March 2028

Quick facts

Lead sponsorSohag University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment200
Start date1 April 2026
Primary completion1 March 2027
Estimated completion1 March 2028

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

Adults 30 to 75, any sex, with Diabetic Nephropathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study the relation between irisin level and progression of diabetic nephropathy and its early detection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetic Nephropathies

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07435480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing